Φορτώνει......

Dabrafenib in BRAF V600E–Mutant Advanced Non-Small Cell Lung Cancer: an Open-label, Single arm, Multicenter, Phase 2 Trial

BACKGROUND: Activating BRAF V600E mutations are found in approximately 1–2% of adenocarcinomas of the lung offering an opportunity to test targeted therapy for this disease. Dabrafenib is an oral selective inhibitor of the BRAF kinase. The aim of this study was to assess the clinical activity of dab...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	Lancet Oncol
Κύριοι συγγραφείς:	Planchard, David, Kim, Tae Min, Mazieres, Julien, Quoix, Elisabeth, Riely, Gregory, Barlesi, Fabrice, Souquet, Pierre-John, Smit, Egbert F., Groen, Harry J. M., Kelly, Ronan J., Cho, B. C., Socinski, Mark A., Pandite, Lini, Nase, Christine, Ma, Bo, D’Amelio, Anthony, Mookerjee, Bijoyesh, Curtis, C. Martin, Johnson, Bruce E.
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	2016
Θέματα:	Article
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5006181/ https://ncbi.nlm.nih.gov/pubmed/27080216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)00077-2
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Dabrafenib in BRAF V600E–Mutant Advanced Non-Small Cell Lung Cancer: an Open-label, Single arm, Multicenter, Phase 2 Trial

Παρόμοια τεκμήρια